PGPIPN vs Follistatin
Side-by-side comparison of key properties, dosing, and research.
Immune Support
PGPIPNAnabolic & IGF
Follistatin- Summary
- PGPIPN is a bioactive hexapeptide (Pro-Gly-Pro-Ile-Pro-Asn) derived from beta-casein during enzymatic digestion. It exhibits anti-inflammatory properties via opioid receptor modulation and cytokine suppression, making it relevant for gut health, systemic inflammation, and as a component of casein-derived functional foods.
- Follistatin is an endogenous glycoprotein that acts as a potent inhibitor of myostatin and activin, two proteins that limit muscle growth. By binding and neutralizing myostatin, follistatin removes the primary brake on skeletal muscle hypertrophy, enabling significant muscle growth beyond normal physiological limits. It is distinct from its isoforms Follistatin 315 and Follistatin 344 in tissue distribution and binding affinity.
- Half-Life
- Estimated 30-120 minutes (peptide degradation)
- ~3–5 hours (endogenous form)
- Admin Route
- Oral, Subcutaneous (research)
- IM, SubQ
- Research
- —
- —
- Typical Dose
- 200-500 mg per day
- 50–100 mcg per injection site
- Frequency
- Once or twice daily
- Every other day or 2–3x per week
- Key Benefits
- Anti-inflammatory effects via cytokine suppression
- Gut mucosal protection and intestinal barrier support
- Opioid receptor modulation for gut motility regulation
- Potential analgesic activity via central and peripheral opioid pathways
- Explored for inflammatory bowel conditions and gut dysbiosis
- Natural origin (food-derived) with favorable safety profile
- Potent myostatin inhibition enabling supraphysiological muscle growth
- Increases skeletal muscle mass and fiber size
- May accelerate recovery from muscle injury
- Potential benefits in muscular dystrophy and sarcopenia
- Synergistic with IGF-1 and growth hormone in anabolic protocols
- Animal studies show dramatic increases in muscle mass
- Reduces muscle fibrosis in dystrophic models
- Side Effects
- Generally very well-tolerated given food-derived origin
- Theoretical opioid-mediated constipation at high doses
- Rare milk protein allergy in casein-sensitive individuals
- Potential for excessive muscle growth if doses are not controlled
- FSH suppression with implications for fertility in women
- Theoretical risk of cardiac hypertrophy with prolonged high-dose use
- Limited human safety data available
- +1 more
- Stacks With
- —
- —